The Path To Commercialize CAR-T Cell Products
Share This:
                           

About The Author

Christian Chabannon is a PhD at Institut Paoli Calmettes · Centre de Therapie Cellulaire. Departement de Biologie du Cancer. Chabannon is also the Coordinator of the « Centre d’Investigations Cliniques en Biothérapies de Marseille | Professor of Cell Biology at Aix-Marseille University.

                       

The Path To Commercialize CAR-T Cell Products

Different cancer treatments exist, but they each have variable efficacies and non-negligible side effects Many innovative approaches are under development in research labs or are being tested in phase I/II trials. Among such treatments are genetically-engineered CAR T cells that bypass the natural function of patients’ T cells to efficiently target and kill tumors. Two CAR T cell products were recently approved by the FDA, and their administration is limited to certified centers in the US. Dedicated manufacturing setups are...

Read more